← Back to Screener
Arcellx, Inc. Common Stock (ACLX)
Price$115.07
Value ScoreF
Growth ScoreF
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)31.48%
Price vs S&P 500 (4W)-8.32%
VGM Score35.03
Market Capitalization$6.73B
All Metrics
Book Value / Share (Quarterly)$6.95
P/TBV (Annual)12.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.67
Price vs S&P 500 (YTD)72.14%
Net Profit Margin (TTM)-1028.05%
EPS (TTM)$-4.06
10-Day Avg Trading Volume2.16M
EPS Excl Extra (TTM)$-4.06
EPS (Annual)$-4.07
ROI (Annual)-56.90%
Cash / Share (Quarterly)$7.77
Revenue Growth QoQ (YoY)-89.17%
ROA (Last FY)-37.90%
Revenue Growth TTM (YoY)-79.35%
EBITD / Share (TTM)$-4.37
ROE (5Y Avg)-49.03%
Operating Margin (TTM)-1138.31%
Cash Flow / Share (Annual)$-3.67
P/B Ratio16.72x
P/B Ratio (Quarterly)9.37x
Net Income / Employee (Annual)$-1,095,400
EV / Revenue (TTM)298.35x
ROA (TTM)-36.27%
EPS Incl Extra (Annual)$-4.07
Current Ratio (Annual)4.44x
Quick Ratio (Quarterly)4.36x
3-Month Avg Trading Volume1.23M
52-Week Price Return80.62%
Revenue / Employee (TTM)$106,600
Tangible BV / Share (Quarterly)$5.47
P/S Ratio (Annual)301.95x
Asset Turnover (Annual)0.04x
52-Week High$115.13
EPS Excl Extra (Annual)$-4.07
CapEx CAGR (5Y)21.19%
26-Week Price Return38.04%
Quick Ratio (Annual)4.36x
13-Week Price Return67.96%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.44x
Enterprise Value$6.65B
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$106,600
Pretax Margin (Annual)-1026.95%
Cash / Share (Annual)$7.77
3-Month Return Std Dev153.63%
Net Income / Employee (TTM)$-1,096,200
ROE (Last FY)-56.90%
EPS Basic Excl Extra (Annual)$-4.07
P/FCF (TTM)24.85x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.06
ROI (TTM)-55.46%
P/S Ratio (TTM)301.95x
Revenue / Share (Annual)$0.40
Tangible BV / Share (Annual)$4.65
Price vs S&P 500 (52W)50.74%
Year-to-Date Return76.49%
5-Day Price Return0.02%
EPS Normalized (Annual)$-4.07
ROA (5Y Avg)-34.43%
Net Profit Margin (Annual)-1027.25%
Month-to-Date Return0.22%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$-4.38
Operating Margin (Annual)-1135.61%
LT Debt / Equity (Annual)10.18x
ROI (5Y Avg)-44.98%
LT Debt / Equity (Quarterly)2.16x
EPS Basic Excl Extra (TTM)$-4.06
P/TBV (Quarterly)9.75x
P/B Ratio (Annual)9.37x
Pretax Margin (TTM)-1027.87%
Book Value / Share (Annual)$6.95
Price vs S&P 500 (13W)65.65%
Beta0.36x
P/FCF (Annual)35.99x
Revenue / Share (TTM)$0.39
ROE (TTM)-55.46%
52-Week Low$60.35
vGradeF
gGradeF
mGradeA
vgmGradeD
Show chart for
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.23
3.42
2.78
2.64
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ACLXArcellx, Inc. Common Stock | F | F | A | $115.07 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Arcellx is a clinical-stage biotechnology company developing cell-based immunotherapies for cancer and other difficult-to-treat diseases. The company's pipeline targets blood cancers including multiple myeloma and acute myeloid leukemia, along with solid tumors and select non-oncology indications.